Liver transplantation: post-transplant management by Halliday, N & Westbrook, RH
British Journal of Hospital Medicine
 
Adult liver transplantation in the United Kingdom (II): post-transplant management
--Manuscript Draft--
 
Manuscript Number: hmed.2016.0140R1
Full Title: Adult liver transplantation in the United Kingdom (II): post-transplant management
Short Title: Adult liver transplantation in the United Kingdom (II)
Article Type: Review
Keywords: Liver transplant;  complications;  quality of life;  immunosuppression;  infection;
rejection
Corresponding Author: Neil Halliday, MBBS Bsc(Hons)
University College London Medical School
London, UNITED KINGDOM
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University College London Medical School
Corresponding Author's Secondary
Institution:
First Author: Neil Halliday, MBBS Bsc(Hons)
First Author Secondary Information:
Order of Authors: Neil Halliday, MBBS Bsc(Hons)
Rachel Westbrook
Order of Authors Secondary Information:
Abstract: Medical care for patients following liver transplantation is complex and requires a
holistic approach to management. Patients and clinicians are faced with multiple
challenges: immunosuppressive regimens must be optimised to avoid and treat graft
rejection; the risk and atypical features of sepsis in the immunocompromised patient
must be recognised; steps are required to reduce the recurrence of liver disease and
the long term increased risks of malignancy; renal failure and metabolic complication
need managing. Despite the benefits of liver transplantation there are additional
concerns regarding its impact upon quality of life. This review will focus upon the care
of patients following liver transplantation. As these patients will present to a broad
range of clinicians, an understanding of the common drugs used post transplantation
and general approach to management of these patients will be of benefit to the general
clinical audience.
Suggested Reviewers:
Additional Information:
Question Response
Please enter the word count of your
manuscript
2650
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
  
 
 
 
 
British Journal of Hospital Medicine:  
 
 
Adult liver transplantation in the United Kingdom (II): post-transplant management 
Neil Halliday & Rachel H Westbrook 
 
 
Corresponding Author: 
Neil Halliday; neilhalliday@nhs.net 
 
 
Manuscript details: 
 
Pages: 18 
Word Count: 2650 
Tables: 3 
Figures: 3 
 
 
 
 
 
 
 
 
Title page
1 
 
Adult liver transplantation in the United Kingdom (II): post liver transplant management. 
 
Abstract 
Medical care for patients following liver transplantation is complex and requires a holistic approach 
to management. Patients and clinicians are faced with multiple challenges: immunosuppressive 
regimens must be optimised to avoid and treat graft rejection, the risk and atypical features of sepsis 
in the immunocompromised patient must be recognised, steps are required to reduce the 
recurrence of liver disease and the long term increased risks of malignancy, renal failure and 
metabolic complication need managing. Despite the benefits of liver transplantation there are 
additional concerns regarding the impact upon quality of life. This review will focus upon the  care of 
patients following liver transplantation. As these patients will present to a broad range of clinicians, 
an understanding of the common drugs used post transplantation and general approach to 
management of these patients will be of benefit to the general clinical audience.  
 
Key Points and Key Words 
Liver transplantation offers a survival benefit for patients with acute and chronic liver 
diseases and primary liver cancer 
Immunosuppressive medications have interactions with many commonly prescribed drugs 
and prescribers should be aware of these 
Immunosuppression regimens are individualised depending upon primary liver disease, 
rejection, co-morbidities and intolerances 
The range of common infections affecting post-transplant patients differs from the general 
population and changes with time from transplantation 
Acute cellular rejection is typically an early complication following transplantation  
Patients are at increased risk of metabolic, cardiovascular and malignant and renal 
complications 
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Despite the clear mortality benefit for patients there are concerns regarding quality of life 
outcomes for some patients 
Liver transplant, complications, quality of life, immunosuppression, infection, rejection  
 
Liver transplantation (LT) is a life-saving treatment for patients with acute liver failure, 
decompensated chronic liver disease (CLD) and hepatocellular carcinoma. This article reviews the 
common immunosuppression regimens and complications including infection, graft rejection, 
metabolic complications, malignancy, disease recurrence, de novo renal disease and the impact 
upon quality of life following LT. 
 
Survival after Liver Transplantation 
In the pre LT era patients with decompensated CLD would die within months whereas LT 
recipients now have survival rates in excess of 90% and 80% at 1 and 5 years respectively.  
(Neuberger, 2016) The early survival following LT has steadily improved over the last 2 decades and 
this is likely to reflect experience in selection of patients, improved surgical technique and 
developments in the efficacy and tolerability of immunosuppressive therapy.  (Watt et al., 2010, 
Adam et al., 2012) (Figure 1) Although LT outcomes are improving and the procedure is undoubtedly 
is life saving for selected patients; survival after LT is significantly inferior to age matched  non 
transplant recipients. (Barber et al., 2007) Moreover longer term survival after LT is less impressive 
with little significant reduction in late morbidity and mortality over the last 2 decades. (Adam et al., 
2012, Lodhi et al., 2011) Ten year survival rates are 60% with the leading causes of death being 
cardiovascular, malignancy, infection and renal failure with liver related mortality from chronic 
rejection or disease recurrence contributing to a relatively small proportion of late mortality. (Watt 
et al., 2010)(Figure 2) With the number of liver transplants performed annually in the UK increasing 
combined with improved survival following LT this will result in general physicians/surgeons and 
general practitioners encountering a greater number of LT recipients in their daily practice. Thus a 
general awareness of the management of such patients and the longer term health problems they 
are likely to encounter needs to be appreciated.  
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Immunosuppression 
Immunosuppression is routinely given after liver transplantation to block or interfere with 
the immune response and stop the recipient’s immune system identifying the LT graft as foreign and 
attempting to destroy it. The common agents, their associated side effects and interactions with 
commonly prescribed medications are detailed in table 1. The initial choice of immunosuppression 
will be made by the LT centre taking into account the patient’s clinical condition, aetiology of liver 
disease, and presence or absence of additional comorbidities. (e .g. renal failure, obesity etc.) Most 
centres will use a calcineurin inhibitor (CNI; tacrolimus or ciclosporin) as their principle 
immunosuppression with over 95% of LT recipients discharged from hospital on a CNI. (Wiesner and 
Fung, 2011) Amongst the CNIs tacrolimus is the favoured drug of choice with superiority over 
ciclosporin in mortality, graft loss and episodes of rejection. (O'Grady et al., 2007) In the immediate 
post LT period corticosteroids are routinely used but rapidly tapered over 4-6 weeks. 
Antimetabolites (azathioprine or mycophenolate mofetil) are often used in conjunction with CNIs to 
either augment immunosuppression to treat/prevent rejection or to reduce the dose of CNI therapy 
when side effects (ie. renal dysfunction) are present. (Wiesner et al., 2001) In current practice 
Mammalian target of rapamycin inhibitors (mTOR) such as sirolimus and everolimus are reserved for 
those patients intolerant to the above therapies.  
In patients with renal impairment pre-LT or who develop acute kidney injury peri -
transplantation, alternative induction agents can be used to avoid the immediate introduction of CNI 
therapy and its associated nephrotoxic effects. Basiliximab is an anti-interleukin 2 receptor antibody 
and its use with the delayed introduction low dose CNI therapy significantly improves renal function 
after LT with no significant increased risk of graft rejection. (Neuberger et al., 2009) 
Immunosuppression therapy has revolutionised survival after LT by significantly reducing the 
rate of graft loss from acute and chronic rejection. However immunosuppressive therapy itself 
contributes significantly to the increased morbidity and mortality LT recipients encounter when 
compared to the general population, increasing the risk of malignancy, metabolic syndrome and 
renal failure. (Doycheva et al., 2016, Fussner et al., 2015, Leithead et al., 2012) (Table 1) Moreover it 
is now evolving that selected patients can achieve tolerance of the graft and immunosuppressive 
therapy can be withdrawn with no long term risk to the graft, coupled with a reduction in 
immunosuppression related morbidity and mortality. (Adams et al., 2015). This approach is only 
considered in highly selected patients, in the setting of clinical trials, however identification of such 
patients is currently being evaluated via a coordinated national study within the United Kingdom. 
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Complications after Liver Transplantation 
Complications following liver transplantation are best thought of in respect to their timing 
after the transplant operation. This is because the nature of complications and their prevalence 
changes as time from the LT operation evolves. Early complications, defined as a complication at < 
6months from the transplant and late complications, >6 months from the LT, are outlined in table 2 
and medical complications are expanded on below. (Table 3) 
 
Infections: 
Infectious complications are a major cause of morbidity and mortality after LT, with in excess 
of 60% of recipients being affected. The prevention, early evaluation and diagnosis of post LT 
infections are critical in the management of a post LT patient. The prevalence of different infections 
following LT changes as the time from transplantation evolves. (Karuthu and Blumberg, 2012)  
In the first weeks following LT the infections encountered by patients are similar to those 
seen in any post-surgical patient on ITU and include wound infections, pneumonia, line infections 
and urinary tract infection. The routine use of antimicrobial prophylaxis in the immediate post-LT 
period had decreased the incidence, severity and mortality from such infections. (Gavalda et al., 
2012) As immunosuppressive therapy is established the patient becomes at risk of atypical i nfections 
including candida, Pneumocystis jirovecii, cytomegalovirus, herpes simplex virus and varicella zoster 
virus. (Hernandez Mdel et al., 2015) A low threshold of suspicion and investigation for such atypical 
infections is required in any post LT patient where infection is suspected. Cytomegalovirus and 
candida infection are the commonest opportunistic infections in LT recipients  and have a significant 
morbidity and mortality if they are not treated early. In light of this many centres give routine CMV 
and candida prophylaxis for the first 3 months post-LT to cover the time when immunosuppression 
levels are often at their highest. (Mumtaz et al., 2015, Eschenauer et al., 2009)  
Fever in the post-LT patient is an emergency, it must always be investigated and antibiotics 
started early if bacterial infection is suspected. Prevention strategies are important and all LT 
patients should be immunised against influenza and pneumococcus; hepatitis B and A vaccination 
should have been administered pre-LT. It is recommended that live vaccines are avoided following 
LT. 
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Graft rejection:  
Acute and chronic graft rejection are beyond the scope of this article, however it should be 
noted that acute cellular rejection is common and mild acute cellular rejection is manged by 
augmentation of baseline immunosuppression and in moderate/severe rejection intravenous 
corticosteroids are typically used.  
 
Metabolic syndrome and cardiovascular disease: 
 Cardiovascular disease (CVD) is increased significantly above that of the general population 
following LT. Death from CVD is the leading cause of non-liver related late mortality, accounting for 
almost 25% of deaths after 5-years. (Madhwal et al., 2012, Desai et al., 2010, Watt et al., 2009) The 
reason for this significant mortality is multifactorial. The metabolic syndrome, which incorporates 
insulin resistant diabetes mellitus, obesity, dyslipidaemia and arterial hypertension, affects between 
50-60% of post LT recipients. (Watt and Charlton, 2010) Individually reported studies describe the 
prevalence of diabetes mellitus in 10-64% of LT recipients, obesity (BMI>30kg/m²) in 24-64%, 
dyslipidaemia in 40-66% and arterial hypertension in 40-85%. (Lucey et al., 2013, Luca et al., 2015)  
Immunosuppression therapy is recognised to either exacerbate or cause de novo arterial 
hypertension, diabetes, dyslipidaemia and obesity in the post LT population (Barnard et al., 2016), 
thus increasing cardiovascular risk (Table 3). Moreover the conventional risk factors that place a 
patient at risk for the metabolic are often prevalent in pre-LT populations such as those transplanted 
for non-alcoholic fatty liver disease. Smoking is common in certain disease aetiologies pre -LT, 
including hepatitis C and alcohol related liver disease, and continuation to smoke further compounds 
the risk of cardiovascular disease post-LT. 
Aggressive management of CVD risk factors post-LT and immunosuppressive minimisation 
where possible, is essential if a positive impact on late morbidity and mortality is to be achieved. 
Hypertension should be aggressively treated with a target blood pressure of 130/80. First line 
antihypertensive therapies are dihydropyridine calcium channel blockers (amlodipine / nifedipine). 
Statin therapy should be considered and commenced in patients with cardiovascular disease, type 2 
diabetes and those with an elevated 10 year CVD risk of greater than 7.5%.  Statin therapy may 
interact with CNI, resulting in increased statin concentrations and risk of rhabdomyolysis as both are 
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metabolised by cytochrome P450-3A4. Pravastatin and Fluvastatin are the statins of choice post-LT 
as they are not metabolised by the cytochrome P450-3A4. Finally the benefit of education regarding 
a healthy diet and regular exercise programs should not be discarded.  
 
Malignancy: 
 De novo malignancy after CVD is the leading cause of late morbidity and mortality after LT. 
Liver transplant recipients have a 2-3 fold increased risk of solid organ cancers, a 30 fold increase in 
lymphoproliferative cancers and up to 70 fold increase in squamous / basal call skin carcinomas  
compared to the general population. (Watt et al., 2009) The risk of solid organ cancers increases 
with time from LT. (Engels et al., 2011) Risk reduction is focussed on controlling modifiable risk 
factors including immunosuppression minimisation, sun avoidance, alcohol and smoking cessation, 
however many risk factors cannot be modified. (Carenco et al., 2015) (Immunosuppression, 
aetiology for LT, increasing patient and graft age) Despite the recognised increased relative risk of de 
novo cancers in the LT population, cancer surveillance strategies have yet to definitively prove an 
overall impact cancer related mortality.   
 Patients with alcohol related liver cirrhosis as their indication for LT are particularly at risk of 
upper gastrointestinal, oropharyngeal and lung cancers. A smoking history pre and post-LT further 
increases the risk of head/neck/lung carcinoma highlighting the importance of smoking cessation pre 
and long-term post LT. (Herrero et al., 2011, Watt et al., 2009) Patients with primary sclerosing 
cholangitis and associated inflammatory bowel disease are at a significantly increased risk of 
colorectal carcinoma and annual screening colonoscopies are recommended in such patients. (Watt 
et al., 2009) 
Post-Transplant lymphoproliferative disorder (PTLD) primarily effects younger recipients and 
can occur any time following LT. Epstein Barr Virus (EBV) has an aetiological role in 80%; with EBV 
causing proliferation of B lymphocytes, which in the context of immunosuppression is not inhibited, 
resulting in mutations and PTLD. Symptoms include fever, weight loss , night sweats and 
lymphadenopathy; cytopaenias and a raised LDH on a blood count are suggestive, however for a 
definitive diagnosis histology is required.  The management is a reduction in immunosuppression 
and if unsuccessful chemotherapy.  
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Disease Recurrence: 
Certain liver pathologies resulting in the need for LT can reoccur following LT; with the 
frequency varying depending on the primary disease. (Figure 3) Conversely other causes of chronic 
liver disease are cured by LT; these include alpha 1 anti-trypsin deficiency, haemochromatosis and 
Wilson’s disease. 
To-date hepatitis C is reported in the literature as having the highest rate of recurrence post-
LT, occurring in 100% of those patients who were HCV RNA positive at the time of LT.  (Westbrook 
and Dusheiko, 2014) Progression of hepatitis C is accelerated following LT resulting in hepatitis C 
infected recipients having a poorer graft and patient survival. (Forman et al., 2002) Such patients 
should undergo regular assessment of graft fibrosis via a combination of some or all of transient 
elastography, liver histology and indirect measurement of portal pressure to identify those at 
greatest risk and whom will benefit from early HCV treatment. However given the recent advent of 
and increased access to direct acting anti-viral therapy it is now the norm for HCV to be eradicated 
prior to LT. Interferon-free, direct acting anti-viral regimens allow eradication of HCV infection, with 
high efficacy, in patients with decompensated liver disease whilst awaiting transplantation meaning 
this will become a much rare cause of disease recurrence post-LT in future years. (Gambato et al., 
2014, Charlton et al., 2015) In those patients with hepatitis C recurrence following transplantation, 
there is growing evidence that direct acting antivirals have high sustained virological response rates 
despite immunosuppression (Suraweera et al,. 2016). However, some regimens require careful 
monitoring and dose adjustment due to interactions with calcineurin inhibitors.   
Hepatitis B virus can be prevented post-LT by the use of Hepatitis B immunoglobulin in the 
immediate post-LT period and nucleoside analogues (tenofovir/entecavir) long-term. (Gane et al., 
2007, Fung et al., 2013)  
Recurrent or de novo non-alcoholic fatty liver disease is commonly seen post-LT due to the 
increased prevalence of the metabolic syndrome secondary to immunosuppression use and its 
preventative management is detailed above.  
The autoimmune liver diseases including primary biliary cirrhosis, autoimmune hepatitis and 
primary sclerosing cholangitis can all re-occur post LT in 10-50% of recipients, although actual rates 
of graft loss are significantly lower especially in primary biliary cirrhosis. (El-Masry et al., 2011)   
Relapse rates to alcohol following LT for alcohol related liver cirrhosis are highly variable (10-
50%) secondary to no accepted definition of relapse. (Faure et al., 2012) Whilst occasional drinking 
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may not impact on graft survival, 20% of relapsers will progress to harmful drinking which impacts 
on graft and patient survival. (Faure et al., 2012)  
Finally patients transplanted for hepatocellular carcinoma (HCC) within Milan criteria, have a 
risk of HCC recurrence between 8-20% during the first 2-years with an associated very poor 
prognosis. (Clavien et al., 2012)  
 
Renal Disease: 
Renal disease is a well-recognised complication post-LT and is associated with an increase in 
long-term morbidity and mortality. Aetiology is multifactorial contributed to by CNI therapy, renal 
dysfunction pre-LT, peri-operative acute renal failure, diabetes and hypertension. Overall 
approximately 50% of post-LT patients with develop chronic kidney disease stage 3/4 with 5-9% 
requiring dialysis by 10-years post LT. (Ojo et al., 2003) 
 All LT patients should avoid nephrotoxic dugs (NASIDS) and should have their hypertension 
and diabetes aggressively controlled. In patients with progressive renal disease changing 
immunosuppressive therapy to a “CNI sparing / CNI free” regimen should be considered by the 
transplant centre.   
  
Quality of life after Liver Transplantation 
 As discussed above LT, although life-saving, carries with it significant medical and surgical 
morbidity and mortality and many patients have valid concerns regarding quality of life (QOL) 
following LT as opposed to merely increased length of survival.  
 Quality of life has been assessed post-LT in several short term studies which have 
demonstrated encouraging results however data on the longer term evaluation of QOL is less 
convincing. (Yang et al., 2014) Physical and mental functioning along with life satisfaction scores 
improve short and long term post-LT. (De Bona et al., 2000) Whereas data regarding anxiety and 
depression show convincing short term improvement but less convincing longer term outcomes with 
anxiety regarding disease recurrence and side effects of medication predominating.  The percentage 
of LT recipients who return to work after transplantation averages about 40%; with improved 
reported QOL in those employed vs. unemployed. (Aberg et al., 2012)  
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Sexual dysfunction improves post-LT but remains problematic with high rates of erectile 
dysfunction, reduced libido and difficulty reaching orgasm. For women of childbearing age fertility is 
restored and with it comes realistic prospects for starting a family.  
Overall, QOL studies in post LT patients are similar to those in kidney, heart and lung 
transplant recipients, however they show inferiority when compared with sex and age matched 
healthy individuals.  
Conclusions 
Following liver transplantation, patients have complex care needs and optimal care will 
reduce the risk of recurrence of the primary liver disease, protect the graft from rejection and 
minimise the risk of complications of immunosuppressive drugs. Despite this there is an increased 
risk of malignancy, renal failure, metabolic and cardiovascular diseases. Focussed assessment and 
optimisation of these risks is key to improving long term survival, which remains below age-
matched, non-transplanted controls.  
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Figure 1: Improving survival in liver transplantation over the last 20 years. 
 
 
 
 
Taken from: Evolution of indications and results of liver transplantation in Europe. A report from the 
ELTR. Adam R, Karam V, Delvart V et al. J Hepatol. 2012 
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Figure 2: Causes of late mortality following Liver Transplantation 
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Bone marrow suppression 
Gastrointestinal upset (abdominal pain, 
nausea, vomiting, diarrhoea) 
 
Azathioprine 
 
Bone marrow suppression 
Gastrointestinal side effects (nausea, 
pancreatitis) 
Dermatitis 
Allopurinol 
Mammalian target of 
rapamycin (mTOR) 
inhibitors  
(sirolimus, everolimus) 
 
Hypertriglyceridaemia 
Pneumonitis (sirolimus) 
Nephrotic syndrome (sirolimus) 
Mouth ulcers (sirolimus) 
Impaired wound healing 
 
Table 1: Common adverse effects of immunosuppressive agents used in liver 
transplantation 
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Table 2: Complications following Liver Transplantation. 
Early < 6 months  
Graft • Primary non function 
• Delayed graft function 
Surgical • Bleeding 
• Hepatic artery thrombosis 
• Venous thrombosis 
• Bile leak 
• Anastomotic stricture – Biliary 
Medical • Infections 
• Rejection 
Late > 6 months  
Graft • Ischaemic cholangiopathy 
Surgical • Biliary anastomotic stricture 
• Vascular stricture 
• Hepatic artery thrombosis 
• Incisional hernia 
Medical • Infections 
• Late rejection / chronic rejection 
• Malignancy 
• Cardiovascular disease 
• Renal impairment 
• Disease recurrence 
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Table 3: Long Term Complications of Liver Transplantation 
Health Problem Incidence Risk Factors Associated Immunosuppression 
Mood disorders 20-25% Hepatitis C  
Hypertension 40-85%  Tacrolimus 
Ciclosporin 
Corticosteroids 
CVS Disease 9-25% Male 
Ethnicity 
FHx 
HT 
DM 
NASH 
 
Dyslipidaemia 45-69%  Sirolimus 
Ciclosporin 
Steroids 
Diabetes 30-40% Ethnicity 
Obesity 
FHx 
Pre LT Diabetes 
Corticosteroids 
Tacrolimus 
Renal 
insufficiency 
14-25% Age 
Diabetes 
Hypertension 
Post LT acute kidney 
injury 
Tacrolimus 
Ciclosporin 
Obesity 30-35%  Corticosteroids 
Malignancy  Sun Exposure 
Smoking 
Ciclosporin 
Tacrolimus 
Azathioprine 
Bone Disease 30-35% Poor nutrition 
Immobility 
Smoking 
Sarcopenia 
Smoking 
Alcohol 
Corticosteroids 
Ciclosporin 
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Figure 3: Graft loss secondary to disease recurrence by aetiology of liver disease. 
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